Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Contrafect (CFRX)

Contrafect (CFRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
ContraFect: Q3 Earnings Snapshot

ContraFect: Q3 Earnings Snapshot

CFRX : 0.0500 (-27.95%)
ContraFect: Q2 Earnings Snapshot

ContraFect: Q2 Earnings Snapshot

CFRX : 0.0500 (-27.95%)
ContraFect: Q1 Earnings Snapshot

ContraFect: Q1 Earnings Snapshot

CFRX : 0.0500 (-27.95%)
ContraFect: Q4 Earnings Snapshot

ContraFect: Q4 Earnings Snapshot

CFRX : 0.0500 (-27.95%)
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis

YONKERS, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a biotechnology company focused on the discovery and development...

CFRX : 0.0500 (-27.95%)
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections

YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the...

CFRX : 0.0500 (-27.95%)
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022

YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the...

CFRX : 0.0500 (-27.95%)
ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late clinical-stage biotechnology company focused...

CFRX : 0.0500 (-27.95%)
ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update

Phase 3 DISRUPT study achieves enrollment of MRSA patients necessary for DSMB to conduct interim futility analysis...

CFRX : 0.0500 (-27.95%)
Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV

LOS ANGELES, CA / ACCESSWIRE / April 27, 2022 / SNN Network presents the Planet MicroCap Showcase taking place on May 3-5, 2022, where 88 MicroCap public and private companies will be presenting at Bally's...

CHL.AX : 1.600 (-2.14%)
DCM : 25.60 (-1.35%)
DDDX : 0.0144 (+1.41%)
AAT.VN : 0.020 (unch)
AATGF : 0.0398 (+109.47%)
ASTR.VN : 0.150 (+3.45%)
AMI.VN : 0.135 (unch)
AUUD : 1.7000 (-1.73%)
AYRO : 1.1600 (-0.85%)
BNXA.VN : 0.670 (unch)
BNXAF : 0.4725 (+3.35%)
BICX : 0.7500 (unch)

Barchart Exclusives

5 Stocks to Buy on Surging AI Data Center Demand
Financial services giant Goldman Sachs remains bullish on AI data center demand. Here are five stocks they like to play the investing megatrend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar